The study conducted by the University of Freiburg explores the potential of sodium bicarbonate (Bicanorm) to enhance the efficacy of donor lymphocyte infusions in relapsed AML patients. Given the limited survival benefits associated with DLIs alone, this research could position sodium bicarbonate as a novel adjunct therapy, potentially expanding treatment options in the AML market. The findings may attract interest from biopharmaceutical companies focusing on immunotherapy and metabolic modulation in oncology, highlighting a need for further exploration of metabolic interventions in hematological malignancies. The competitive landscape may shift if sodium bicarbonate demonstrates significant efficacy, prompting further investment and development in this therapeutic area.